GSK Stock Recent News

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The Food and Drug Administration's independent panel of advisors on Wednesday recommended GlaxoSmithKline's RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over nervous system disorders that may be tied to the shot.

Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

Options traders are making big bets on the upside for healthcare, particularly in shares of  GSK plc GSK.

GSK PLC (LSE:GSK, NYSE:GSK) is moving its global headquarters back to central London in 2024 in a major boost for the West End economy relocating from its current base in Brentford where it has been since 2002. The 10 storey building (currently known as Earnshaw) is on the corner New Oxford Street and Earnshaw Street and is scheduled for completion next year.

Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline GSK, -0.72% to develop oligonucleotide therapeutics.

Analysts at Citi have lowered their price target for GSK PLC (LSE:GSK, NYSE:GSK) to 1,545p from 1,975p to reflect the limited visibility investors enjoy over the ultimate magnitude of Zantac ulcer drug liabilities. This is coupled with negative prior expectations for the bellwether Zantac case in Oakland, California, scheduled for February 2023, they added.

GSK PLC (LSE:GSK, NYSE:GSK) shares fell despite a double dose of positive news, with the EU medical regulator accepting its application for a myelofibrosis treatment and success in a Phase-3 endometrial cancer trial. The European Medicines Agency (EMA) validated the marketing authorisation application for momelotinib, the FTSE 100-listed drugmaker's potential new oral treatment for myelofibrosis, a rare blood cancer.